一種目前正在研發(fā)的新型心臟功能造影劑，能夠幫助患者在靜息狀態(tài)下評(píng)估急性和慢性冠狀動(dòng)脈疾病。

FluoroPharma公司(Boston, MA, USA)已經(jīng)宣布開始I期臨床試驗(yàn)，評(píng)估該公司的新型正電子發(fā)射掃描成像(PET)造影劑CardioPET，此項(xiàng)臨床試驗(yàn)已經(jīng)得到了學(xué)術(shù)評(píng)估委員會(huì)(IRB)的批準(zhǔn)。I期臨床試驗(yàn)是單中心、開放標(biāo)簽的臨床研究，主要是在健康受試者中評(píng)估CardioPET作為心肌成像示蹤劑的安全性、體內(nèi)分布和放射劑量。

這項(xiàng)研究是由Alan Fischman醫(yī)生主持的，他是美國(guó)麻省總醫(yī)院(MGH; Boston, MA, USA)核醫(yī)學(xué)科的主任。在2006年5月，F(xiàn)luoroPharma公司為CardioPET進(jìn)行了了新藥研制申請(qǐng)(IND)，這是該公司的第一項(xiàng)IND。

 
PET Contrast Agent Images Cardiac Patients at Rest
 
A new cardiac viability imaging agent currently in development allows acute and chronic coronary artery disease to be assessed while patients are at rest.

FluoroPharma, Inc. (Boston, MA, USA), has announced the start of phase I clinical trials for its new positron emission tomography (PET) agent, CardioPET, following institutional review board (IRB) approval of the proposed studies. The phase I trial is a single center, open label study, designed to evaluate safety, distribution, and dosimetry of CardioPET as a PET tracer for myocardial imaging in healthy subjects.

The study will be led by Dr. Alan Fischman, director of the nuclear medicine division at Massachusetts General Hospital (MGH; Boston, MA, USA). In May 2006, FluoroPharma filed an Investigational New Drug (IND) application for CardioPET, which is the company’s first IND.